Shardul Amarchand Mangaldas & Co. Advised Emcure Pharmaceuticals On ₹19,520 Million IPO
Shardul Amarchand Mangaldas & Co. advised Emcure Pharmaceuticals Limited (Issuer) on the IPO of 19,375,070 equity shares
Shardul Amarchand Mangaldas & Co. Advised Emcure Pharmaceuticals On ₹19,520 Million IPO
Shardul Amarchand Mangaldas & Co. advised Emcure Pharmaceuticals Limited (Issuer) on the IPO of 19,375,070 equity shares aggregating to ₹19,520.27 million (approximately USD 234 million), comprising a fresh issue of 7,946,231 equity shares aggregating to ₹8000 million and offer for sale by certain shareholders of 11,428,839 equity shares aggregating to ₹11,520.27 million (the Offer).
The Issue had an overall subscription of 68.50x, with the retail individual portion oversubscribed 7.49x; QIB portion oversubscribed 190.88x, non-institutional bidders (more than 0.20 million – up to 1.00 million) oversubscribed 39.05x and non-institutional bidders (above 1.00 million) oversubscribed 55.39x.
Emcure Pharmaceuticals Limited is a prominent pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
The transaction team at Shardul Amarchand Mangaldas & Co. Comprised Nikhil Naredi (Partner), Priya Awasthi (Partner), Rakshita Poddar (Associate), and Manish Soni (Associate).